Although Bcl‐xL serves as a promoter of various types of cancers due to its antiapoptotic effects, requiring targeted knockdown therapy [17, 18, 19], it has also been found to inhibit inflammation in some diseases due to its antiapoptotic effects [20, 21]. This evidence concerns the gene BCL2L1 and cancer.